The Châtillon-based biotech extends its downward streak mid-session, in a Paris market also oriented lower. The security crosses a technical threshold that has been monitored for several weeks and remains well below its moving averages.
The €1.77 support level gives way and the share remains below all its moving averages
The share price of DBV Technologies declines by 2.14% to €1.74. During the session, it broke through its support level at €1.77 and remains below it. The share thus stands 15.22% below its 20-day moving average and 43.20% below its 200-day moving average.
The decline reaches 25.28% over one month and 39.53% over three months. The RSI at 30 is at the edge of the oversold zone, which underscores the extent of the recent pullback. The SBF 120 is down 0.77%, but DBV ranks among the most underperforming values in the index, at the bottom of the ranking.
Short positions at 4% of capital, up over 30 days
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Declared net short positions reach 4.00% of capital, spread among four funds, according to the declarations reviewed. They have increased by 0.26 percentage points over thirty days, from 3.74%. This level indicates that institutional investors remain positioned to the downside on the security or are seeking to hedge an exposure.
An increase of this magnitude does not signal a sharp reversal, but it aligns with the selling pressure observed for weeks. As a reminder, the company filed its application for biological license with the FDA at the end of September for its peanut allergy patch. When publishing first-half 2026 results on July 16, 2026, it indicated it had cash reserves allowing it to operate until the third quarter of 2027.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1,6 millions de dollars
Quarterly revenue: 1,6 millions de dollars
Net income: -98 millions de dollars
Guidance from the release
DBV is a late-stage biopharmaceutical company currently in regulatory discussions with the FDA, with BLA submission anticipated in Q3 2026; the company reports cash funding into Q3 2027, indicating reliance on capital reserves and no current revenue generation.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
